Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Receivables (2018 - 2025)

Historic Change in Receivables for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Q3 2025 value amounting to -$5.4 million.

  • Ultragenyx Pharmaceutical's Change in Receivables rose 4459.76% to -$5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.8 million, marking a year-over-year increase of 4905.41%. This contributed to the annual value of $33.6 million for FY2024, which is 4750.2% up from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's Change in Receivables stood at -$5.4 million, which was up 4459.76% from $12.7 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Change in Receivables high stood at $24.9 million for Q1 2024, and its period low was -$10.1 million during Q1 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's median Change in Receivables value was $2.0 million (recorded in 2021), while the average stood at $3.7 million.
  • In the last 5 years, Ultragenyx Pharmaceutical's Change in Receivables tumbled by 95555.56% in 2022 and then skyrocketed by 770000.0% in 2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Change in Receivables (Quarter) stood at $3.1 million in 2021, then soared by 196.25% to $9.1 million in 2022, then plummeted by 111.13% to -$1.0 million in 2023, then surged by 2139.53% to $20.6 million in 2024, then plummeted by 126.28% to -$5.4 million in 2025.
  • Its Change in Receivables was -$5.4 million in Q3 2025, compared to $12.7 million in Q2 2025 and -$10.1 million in Q1 2025.